Orforglipron
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
Eli Lilly · Phase 3 · Completed · Enrollment 376
No selected arm has a reported week for this endpoint.
A solid line connects the weeks the source reports.